A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)

Health Technology Assessment

Volumn 15, Issue 21, 2011, Pages 1-132

  Price, D ^a   Musgrave, S ^b   Wilson, E ^b   Sims, E ^b   Shepstone, L ^b   Blyth, A ^b   Murdoch, J ^c   Mugford, M ^b   Juniper, E ^d   Ayres, J ^e   Wolfe, S ^f   Freeman, D ^g   Lipp, A ^h   Gilbert, R ⁱ   Harvey, I ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f Thorpewood Surgery   (United Kingdom)

^g Sheringham Medical Practice   (United Kingdom)

^h Great Yarmouth and Waveney Primary Care Trust   (United Kingdom)

ⁱ Castle Partnership   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEDOCROMIL; PARACETAMOL; PLACEBO; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; STEROID; TERBUTALINE; THEOPHYLLINE; ZAFIRLUKAST;

ADD ON THERAPY; ARTICLE; ASTHMA; BLOATING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUGHING; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC EVALUATION; EMPLOYMENT STATUS; EPILEPSY; ESOPHAGITIS; FINGER SWELLING; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GENERAL PRACTITIONER; HAND DISEASE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH STATUS; HEART PALPITATION; HOSPITAL ADMISSION; HUMAN; LETHARGY; LOW DRUG DOSE; LUNG CARCINOMA; LUNG FUNCTION; MEDICAL PRACTICE; MENTAL DETERIORATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SKIN TINGLING; SLEEP DISORDER; SMOKING; SYMPTOMATOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEALTH STATUS INDICATORS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PSYCHOMETRICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960795874     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15210     Document Type: Article

References (96)

1. Chung F, Barnes N, Allen M, Angus R, Corris P, Knox A, et al. Assessing the burden of respiratory disease in the UK. Respir Med 2002;96:963-75.
2. Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995;108:1228-34.
3. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343:1054-63.
4. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma, 2008, revised 2009. URL: www.sign.ac.uk/guidelines/fulltext/101/index.html.
5. Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention, 2008. URL: www.ginasthma.org.
6. Price D. The Air Study: asthma in real life. Asthma 1999;4:74-8.
7. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
8. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6.
9. Davis BE, Cockcroft DW. Effect of a single dose of montelukast sodium on methacholine chloride PC20. Can Respir J 2005;12:26-8.
10. Riccioni G, Ballone E, D'Orazio N, Sensi S, Di Nicola M, Di Mascio R, et al. Effectiveness of montelukast versus budesonide on quality of life and bronchial reactivity in subjects with mildpersistent asthma. Int J Immunopathol Pharmacol 2002;15:149-55.
11. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-51.
12. van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholineinduced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17:89-95.
13. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139:359-70.
14. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
15. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993;147:1472-6.
16. Dahlen S-E. Leukotrienes as mediators of airway obstruction and bronchial hyperresponsiveness. In: Page C, Gardiner P, editors. Airway hyperresponsiveness: is it really important for asthma? Oxford: Blackwell Scientific; 1993. pp. 188-205.
17. Spector SL. Safety of antileukotriene agents in asthma management. Ann Allergy Asthma Immunol 2001;86:18-23.
18. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77-87.
19. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-tomoderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997;19: 675-90.
20. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998;102:935-42.
21. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20.
22. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999;29:42-51.
23. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
24. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000;132:97-104.
25. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-18.
26. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;160:1862-8.
27. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
28. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;326:621.
29. Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002;110:847-54.
30. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol 2006;97:731-41.
31. Foster JM, van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respir Res 2006;7:131.
32. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
33. Price DB, Rouleau MY, Fletcher CP, Patel P, Olivenstein R, Myhr L, et al. Use of montelukast in tapering inhaled corticosteroid therapy: an openlabel, 48-week trial. Curr Ther Res 2001;62:743-55.
34. Riccioni G, Vecchia RD, Castronuovo M, Ilio CD, D'Orazio N. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Ann Clin Lab Sci 2005;35:285-9.
35. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as addon therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006; Issue 4, Art. No: CD003137.
36. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008;63:453-62.
37. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-52.
38. Price DB. Montelukast: real life effectiveness and cost-effectiveness in primary care. Am J Respir Crit Care Med 1999;158:A816.
39. O'Connor RD, Parasuraman B, Roberts C, Leibman C. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities. Ann Allergy Asthma Immunol 2006;97: 236-43.
40. Drummond M. Economic analysis alongside clinical trials. Research and Development Directorate of the NHS, 1994; F51030-D031 RDDECO.
41. Clark, THJ. Action asthma: the occurrence and cost of asthma. Worthing: Cambridge Medical Publications; 1990.
42. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respir Med 1998;92:351-3.
43. Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinafoate: an analysis of outcomes and costeffectiveness using a primary care database. Respir Med 1998;92:1302-4.
44. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics 1993;4:14-30.
45. Whiteman IA. The management of mild-tomoderate asthmatics in general practice; a retrospective analysis. Br J Med Econ 1993;6:25-35.
46. British Medical Association and the Royal Pharmaceutical Society of Great Britain, British national formulary, 50th edn. London: Pharmaceutical Press; 2006.
47. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003;40:93-101.
48. Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White R, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001;31:845-54.
49. Booth PC. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ 1995;8:65-72.
50. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8.
51. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
52. Laitinen LA. Comparative efficacy of zafirukast & low dose steroids in asthmatics on prn beta-agonists. Eur Respir J 1997;10:419S-20S.
53. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-95.
54. Ringdal N. A comparison of patient preference for treatment with oral zafirlukast or inhaled beclomethasone [abstract P2806]. Eur Respir J 1997;10:437.
55. Chung KF, Naya I. Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. Respir Med 2000;94:852-8.
56. The British Guidelines on asthma management. 1995 review and position statement. Thorax 1997;52:S1-21.
57. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
58. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157:S1-53.
59. Kelly HW. Asthma pharmacotherapy: current practices and outlook. Pharmacotherapy 1997;17: 13-21S.
60. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
61. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-tosevere asthma. Respir Med 2003;97:555-62.
62. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
63. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51.
64. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553-8.
65. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not wellcontrolled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21.
66. Roberts CM, MacRae KD, Winning AJ, Adams L, Seed WA. Reference values and prediction equations for normal lung function in a non-smoking white urban population. Thorax 1991;46:643-50.
67. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132-40.
68. Clinical Effectiveness and Evaluation Unit. Measuring clinical outcome in asthma: a patient focused approach. London: Royal College of Physicians; 1999.
69. Pearson MG, Bucknall CE. Asthma care. Thorax 2000;55:535.
70. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
71. EuroQol Group. EuroQol - a new facility for the management of health related quality of life. Health Policy 1990;16:199-208.
72. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
73. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
74. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjuctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132-40.
75. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
76. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: John Wiley & Sons; 1987.
77. Office for National Statistics. Annual Survey of Hours and Earnings (ASHE), 2005. Basingstoke: Palgrave Macmillan.
78. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
79. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 2005;99:11-19.
80. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62: 219-23.
81. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
82. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
83. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-11.
84. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783-90.
85. McCoy K, Shade DM, Irvin CG, Mastronarde JG, Hanania NA, Castro M, et al. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol 2006;118:1226-33.
86. Vollmer WM, Markson LE, O'Connor E, Frazier EA, Berger M, Buist AS. Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 2002;165:195-9.
87. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118:649-57.
88. Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. Allergy 2008;63:1581-92.
89. Heaton PC. Cost effectiveness of leukotriene modifiers in adults with asthma. Pharmacoeconomics 2006;24:727-42.
90. Greenland S, Finkle, W. D. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995;142:1255-64.
91. Schafer J. The multiple imputation FAQ page, 2009. URL: www.stat.psu.edu/~jls/mifaq.html.
92. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
93. Weinman J, Petrie KJ, Moss-Morris R, Horne R. The Illness Perception Questionnaire: a new method for assessing the cognitive representations of illness. Psychol Health 1996;11:431-45.
94. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001;10:135-40.
95. Horne R, Musgrave S, Lee A, Price D. The Minimal Asthma Assessment Tool (MAAT): a new method for prioritising patients for primary care review by identifying poor asthma control and the causes of poor control. General Practice Airways Group Annual Conference, 2005, 16.
96. Murdoch J. The discursive construction of prophylactic medicine-taking for people with asthma: Interactional issues and moral discourses. PhD thesis. Norwich: University of East Anglia; 2010.